Pandemic H1N1 influenza-associated hospitalizations in children in Madrid, Spain

Teresa del Rosal, Fernando Baquero-Artigao, Cristina Calvo, María J. Mellado, Juan C. Molina, Maria del Mar Santos, María J. Cilleruelo, Mercedes Bueno, Pilar Storch de Gracia, Covadonga Terol, Miguel Á. Roa, Roi Piñeiro, Milagros García López-Hortelano, María L. García-García, Sonia Rodríguez, María Penin, Alejandro Zarauza, Francisco Alvarado, Ana de Blas, Enrique Otheo, Alfonso Rodríguez, María L. Herreros, Alfredo Tagarro, Luis Grande, José T. Ramos, Irene Maté, Cristina Muñoz, Miguel Á. Zafra, María P. Romero-Gómez, Elia Pérez-Fernández, Alberto Delgado, Inmaculada Casas, María E. Cabezas

Objective To describe the epidemiological and clinical characteristics of children hospitalized with 2009 pandemic influenza (pH1N1) in Madrid, Spain.

Patients/Methods We included patients less than 14 years of age admitted to one of 18 hospitals in Madrid, Spain, between May 1 and November 30, 2009 and diagnosed with pH1N1 by polymerase chain reaction. A retrospective chart review was conducted and data were compared by age, presence of high-risk medical conditions, and pediatric intensive care unit (PICU) admission.

Results A total of 517 pH1N1 cases were included for final analysis. One hundred and forty-two patients (27.5%) had predisposing underlying illnesses, with immunosuppression (36 children, 7%) and moderate persistent asthma (34, 6.6%) being the most common ones. Patients with underlying medical conditions had longer hospital stays [median 5, interquartile range (IQR) 3–8 days, versus median 4, IQR 3–6, \( P < 0.001 \)] and required intensive care (20.4% versus 5.9%, \( P < 0.001 \)) and mechanical ventilation more frequently than previously healthy children. Globally, intensive care was required for 51 patients (10%) and invasive mechanical ventilation for 12 (2%). Pediatric intensive care unit admission was significantly associated with abnormal initial chest X-ray [Odds Ratio (OR) 3.5, 95% confidence interval (CI) 1.5–8.5], underlying neurological disease, two with leukemia, and one with a malignant solid tumor.

Conclusions Children with underlying medical conditions experienced more severe pH1N1 disease. Risk factors for admission to the PICU included underlying neurological conditions, immunosuppression and abnormal initial chest X-ray.

Keywords 2009 pandemic influenza A (H1N1), hospitalizations, pediatric influenza, pH1N1.

Please cite this paper as: del Rosal et al. (2011) Pandemic H1N1 influenza-associated hospitalizations in children in Madrid, Spain. Influenza and Other Respiratory Viruses 5(6), e544–e551.
Introduction

In April 2009, the first cases of infection by a novel influenza A H1N1 virus (pandemic H1N1 or pH1N1) were registered in Mexico. Since then, the virus spread worldwide causing significant morbidity. The first cases of the new virus in Spain were detected by the end of April 2009. The highest incidence in Madrid occurred in week 43 (October 25–31, 2009), with 375 cases/100 000 inhabitants.

Most infected children had a mild clinical picture, but pH1N1 resulted in an unusually high number of serious cases among young people. Children with underlying health conditions appear to be at higher risk for severe infection. This risk for severe clinical course is highest among children with underlying neurological diseases. Asthma has been described as one of the most common medical conditions among hospitalized children, but to our knowledge, pH1N1 severity has not been analyzed across different asthma severity levels.

The objectives of our study were as follows: (i) to describe the clinical and epidemiological features of hospitalized children with pH1N1; (ii) to compare the characteristics of ward and pediatric intensive care unit (PICU) patients; and (iii) to evaluate the influence of underlying medical conditions on disease course.

Patients and methods

Patients and samples

Children ≤14 years with confirmed pH1N1 by reverse-transcriptase polymerase chain reaction (RT-PCR) and admitted to one of 18 public pediatric hospitals in Madrid during a 7-month period (May–November 2009) were included in the study. Older children and those referred from other cities of Spain to PICU in Madrid were excluded from the analysis. All centers routinely tested for pH1N1 every child admitted with fever and respiratory symptoms up to December 2009, as pH1N1 activity markedly declined afterwards in Spain. Up to May 22nd, all positive children were admitted to hospital for isolation purposes. After this date, they were only admitted if the clinical picture recommended to do so.

Samples were collected according to the protocol that the Health Department of the Madrid Government set up at the beginning of the pandemic. They were sent to one of the Influenza Laboratories Network of Madrid and processed within 24 hours of collection. The diagnosis of pH1N1 was made with the World Health Organisation approved real-time PCR A H1N1 assay in all laboratories.

Clinical assessment

A retrospective chart review was conducted using a standardized questionnaire, collecting data concerning demographics, health status, clinical manifestations, laboratory tests and chest X-ray results, complications, and outcome. There was at least one pediatrician in charge of collecting the data at each participating hospital.

Underlying health conditions for influenza-related complications were defined according to the recommendations of the Spanish Association of Pediatrics: respiratory diseases (cystic fibrosis, moderate or severe persistent asthma, and bronchopulmonary dysplasia), hemodynamically significant heart diseases, metabolic diseases (diabetes mellitus, morbid obesity), immunosuppression, neurological and neuromuscular diseases, chronic renal failure, and hemoglobinopathies. Morbid obesity was defined as body mass index at or above the 99th percentile for the child’s age. Asthma severity was established according to the classification of the Spanish Society for Pediatric Pulmonology: children with infrequent intermittent and frequent intermittent asthma had less than five and eight exacerbations per year, respectively, remaining completely asymptomatic between them. In contrast, patients with moderate persistent asthma had wheezing episodes at least each 4–5 weeks, with mild symptoms between exacerbations and nocturnal symptoms up to two nights per week. Children with severe persistent asthma had frequent exacerbations with symptoms between them, wheezing with minimal physical efforts and nocturnal symptoms more than two nights per week.

Complications among patients hospitalized with confirmed pH1N1 were identified by using data from the discharge summaries and medical records. Respiratory insufficiency was defined as the need for mechanical ventilation (invasive or non-invasive) in patients without asthma. Children who were admitted to PICU because of asthma exacerbation were considered as having severe bronchospasm. We identified patients with suspected or confirmed bacterial pneumonia taking into account the data regarding blood tests, chest X-ray (focal infiltrates or consolidation, pleural effusion), blood cultures, and clinical course. Patients who had altered mental status for ≥24 hours were categorized as having encephalopathy.

Statistical analysis

We described the characteristics of children with pH1N1 who were admitted to hospital. Clinical features and outcomes were compared according to age and the presence of underlying health conditions. We also compared PICU and ward patients to identify potential risk factors for a more severe clinical course.

Data analysis was performed at the Biostatistics Unit of Hospital La Paz, using spss statistical software, version 9.0.
Continuous variables were described with mean and standard deviation or median and interquartile range. Categorical variables were described with absolute and relative frequencies.

The association of possible risk factors and PICU admission was studied using Chi-square test and Fisher’s exact test in categorical variables and Student’s *t* and Mann–Whitney *U* tests in continuous variables. The area under the ROC curve was estimated to evaluate the discriminating capacity of lymphocyte count, choosing 1840 cells/mm³ as the cut-off that maximized sensitivity (76.2%, 95% CI: 61.5–86.5) and specificity (49.6%, 95% CI: 44.8–54.5).

Finally, all factors that had a significant association (*P* < 0.05) with PICU admission were put into a full model for multiple logistic regression analysis. To estimate the predictive capacity of the model, the area under the ROC curve was calculated.

A two-tailed *P* value < 0.05 was considered statistically significant.

**Results**

**Clinical and demographic characteristics**

During the study period, 517 children with confirmed pH1N1 infection were hospitalized. The first pediatric case was confirmed on the 20th of May and hospitalizations for pH1N1 peaked at the end of October. Cases included in this review represent 90% of confirmed hospitalized pediatric cases in Madrid, according to data from the regional epidemiologic bulletin.

Main characteristics of the total study group are presented in Table 1. Mean age was 4.7 ± 3.9 years and 59.8% patients were less than 5 years. Median time to consultation from the beginning of symptoms was 3 days (interquartile range, IQR: 1–5). The most frequent reasons for hospital admission were high fever and respiratory distress. Mean maximal temperature before admission was 38.9°C ± 0.7°C.

One hundred and forty-two patients (27.5%) had high-risk medical conditions, with immunosuppression, moderate persistent asthma, and neurological disease being the most common ones. There were 163 patients (31.5%) with asthma: 87 had infrequent intermittent asthma, 41 frequent intermittent, 34 moderate persistent, and 1 severe persistent asthma. Patients with underlying health conditions were significantly older than those previously healthy (mean age 5.5 ± 3.8 years versus 4.3 ± 3.9 years, *P* < 0.01).

**Radiological, laboratory, and microbiological studies**

Chest radiograph was performed on admission in 432 children (84%). Abnormal chest radiographs were significantly more frequent in children that required PICU admission.

### Table 1. Characteristics of children hospitalized with pandemic H1N1 influenza, Madrid, 2009

|                                | Number of cases | Percentage |
|--------------------------------|-----------------|------------|
| **Gender**                     |                 |            |
| Female                         | 205             | 40         |
| Male                           | 312             | 60         |
| **Age group**                  |                 |            |
| <1 year                        | 99              | 19         |
| 1–5 years                      | 210             | 41         |
| 5–11 years                     | 155             | 30         |
| 11–14 years                    | 53              | 10         |
| **Clinical signs and symptoms**|                 |            |
| Fever                          | 500             | 97         |
| Upper respiratory tract manifestations |          |            |
| Cough                          | 455             | 88         |
| Rhinorrhea                     | 369             | 72         |
| Odynophagia                    | 62              | 12         |
| Breathing difficulty           | 258             | 50         |
| General symptoms               |                 |            |
| Headache                       | 54              | 11         |
| Myalgias                       | 43              | 9          |
| Irritability/malaise           | 196             | 38         |
| Gastrointestinal symptoms      |                 |            |
| Vomiting                       | 144             | 28         |
| Diarrhea                       | 69              | 14         |
| **Chest radiograph**           |                 |            |
| Interstitial pneumonia         | 187             | 43         |
| Lobar or segmental consolidation | 94             | 22         |
| Other radiologic findings      | 19              | 4          |
| (atelectasis, pleural effusion) |                 |            |
| Normal                         | 132             | 31         |
| **Treatment**                  |                 |            |
| Oseltamivir                    | 389             | 76         |
| Antibiotics                    | 264             | 52         |
| Bronchodilators                | 244             | 48         |
| Oxygen supplementation         | 221             | 43         |
| Intravenous fluid therapy      | 204             | 40         |
| **Underlying health conditions** |            |            |
| Moderate or severe persistent asthma | 142 | 27.5 |
| Other chronic lung disorders (e.g., cystic fibrosis, bronchopulmonary dysplasia, obliterant bronchiolitis) | 19 | 3.7 |
| Immunosuppression (because of underlying disease and/or therapy) or immunodeficiency | 36 | 7 |

© 2011 Blackwell Publishing Ltd, *Influenza and Other Respiratory Viruses*, 5, e544–e551
than in ward patients (88% versus 67%, \( P < 0.01 \)). Blood was collected and analyzed for 462 children (89%). Pediatric intensive care unit patients had lower lymphocyte counts (1590 ± 1298 versus 2702 ± 2868, \( P < 0.001 \)). We observed no differences between PICU and ward patients regarding white blood cell count, neutrophils, and C-reactive protein.

Blood cultures were performed in 341 children (66%), but they were positive only in seven patients (excluding bacterial contaminations). The most frequent isolate was *Streptococcus pneumoniae* (six cases). *Streptococcus pyogenes* was identified in one case. There were no infections by *Staphylococcus aureus*.

**Table 1.** (Continued)

| Complications | Number of cases | Percentage |
|---------------|-----------------|------------|
| Neurological or neuromuscular disorders | 30 | 5.8 |
| Heart disease | 27 | 5.2 |
| Diabetes mellitus | 5 | 1.0 |
| Chronic renal disease | 4 | 0.8 |
| Morbid obesity | 3 | 0.6 |
| Hemoglobinopathy | 3 | 0.6 |
| Other | 19 | 3.7 |

*Children may have had more than one of the conditions listed; percentage represents the number with each condition over the total number of children (\( n = 517 \)).

†Children may have had more than one of the complications listed; percentage represents the number with each condition over the total number of children (\( n = 517 \)).

‡Severe laryngitis (2), decompensation of heart disease (2), bactereemia (2), hepatitis (2), hemolytic crises (1), Stevens-Johnson syndrome (1), urinary tract infection (1), acute tonsillopharyngitis (1), erosive gastritis (1), dehydration (1), hyponatremia (1), incomplete Kawasaki disease (1), myositis (1), pneumothorax (1), and interstitial lung disease (1).

**Antiviral treatment, clinical course, and complications**

Antiviral use was reported in 389 children (76%), oseltamivir being the only drug prescribed. Oseltamivir use was more frequent in PICU than in ward patients (86% versus 74.9%, \( P = 0.08 \)) and significantly lower in infants <1 year compared with older children (59.6% versus 79.9%, \( P < 0.001 \)). There were no major adverse effects associated with oseltamivir therapy.

The median length of hospital stay was 4 days (IQR: 3–6). Complications were registered in 132 patients (26%), as listed in Table 1. The most frequent one was suspected or confirmed bacterial pneumonia, which occurred in 72 patients (14.5%), followed by severe bronchospasm requiring PICU admission (16 patients, 3.1%).

When comparing infants less than 1 year of age with older children, we found no differences regarding hospital stay [median (IQR) 4 days (3–6) for both groups, \( P = 0.59 \)], PICU admission (11% versus 10%, \( P = 0.71 \)), and invasive mechanical ventilation (3% versus 2%, \( P = 0.39 \)). Underlying medical conditions (14.1% versus 30.6%, \( P = 0.001 \)) and complications (17.2% versus 27.5%, \( P = 0.04 \)) were less frequent in infants.

As for patients with high-risk medical conditions, they had longer hospital stay [5 days (3–8) versus 4 (3–6), \( P < 0.001 \)] and required PICU admission (20.4% versus 5.9%, \( P < 0.001 \)) and invasive mechanical ventilation (6.3% versus 0.8%, \( P < 0.01 \)) more frequently than previously healthy children.

However, the presence or severity of asthma was not significantly associated with PICU admission or mechanical ventilation. Pediatric intensive care unit admission and invasive mechanical ventilation proportions were respectively 6.9% and 1.1% in patients with infrequent intermittent asthma (\( n = 87 \)), 12.2% and 2.4% in patients with frequent intermittent asthma (\( n = 41 \)), and 11.8% and 2.9% in patients with moderate persistent asthma (\( n = 34 \)). There was only one patient with severe persistent asthma, who required PICU admission but not invasive mechanical ventilation. Among non-asthmatic children (\( n = 354 \)), 9.9% required PICU admission and 2.5% invasive mechanical ventilation (\( P = 0.01 \) for PICU admission and 0.82 for mechanical ventilation, when comparing non-asthmatic and asthmatic children across the different asthma severity levels).

**Risk factors for PICU admission**

Intensive care was required for 51 patients (10%), breathing difficulty being the most frequent reason for admission at the PICU. Comparison of ward versus PICU patients is showed in Table 2.

Thirty-one patients (6%) received non-invasive ventilation and 12 (2%) invasive mechanical ventilation. Of the 12 patients who required invasive mechanical ventilation, nine (75%) had underlying medical conditions and four died. The most frequent underlying medical conditions in these patients were neurological or neuromuscular disorders and immunosuppression (four patients, 33% each).
Table 2. Comparison of characteristics of ward versus pediatric intensive care unit (PICU) patients

|                          | Ward patients (n = 466) | PICU patients (n = 51) | P*  |
|--------------------------|-------------------------|------------------------|-----|
| Male sex                 | 283 (60.7)              | 29 (56.9)              | 0.59|
| Mean age (years)         | 4.7 ± 3.9               | 4.4 ± 3.7              | 0.6 |
| Clinical signs and symptoms |                        |                        |     |
| Fever                    | 452 (97.2)              | 48 (94.1)              | 0.23|
| Upper respiratory tract manifestations |                |                        |     |
| Cough                    | 413 (88.8)              | 42 (82.4%)             | 0.17|
| Rhinorrhea               | 335 (72)                | 34 (69.4)              | 0.69|
| Odynophagia              | 57 (12.4)               | 5 (10.9)               | 0.76|
| Breathing difficulty     | 2.19 (47.2)             | 39 (78)                | <0.001|
| General symptoms         |                        |                        |     |
| Headache                 | 53 (11.6)               | 1 (2.2)                | 0.07|
| Myalgias                 | 42 (9.2)                | 1 (2.2)                | 0.16|
| Irritability/malaise     | 173 (38.4)              | 18 (38.3)              | 0.98|
| Gastrointestinal symptoms |                        |                        |     |
| Vomiting                 | 136 (29.4)              | 8 (16.3)               | 0.05|
| Diarrhea                 | 67 (14.4)               | 2 (4.1)                | 0.04|
| Mean time from symptom onset to hospital admission (days) | 4.1 ± 1.7 | 2.5 ± 1.7 | 0.3 |
| Abnormal chest radiograph | 67%                    | 88%                    | <0.01|
| Blood test results       |                        |                        |     |
| White blood cell count (cells/mm³) | 9994 ± 5988 | 9430 ± 6537 | 0.57|
| Lymphocytes (cells/mm³)  | 2702 ± 2668             | 1590 ± 1298            | <0.001|
| Neutrophils (cells/mm³)  | 6026 ± 4570             | 6804 ± 5981            | 0.41|
| C-reactive protein (mg/l) | 34.3 ± 52.7            | 45 ± 68.6              | 0.31|
| Treatment                |                        |                        |     |
| Oseltamivir              | 346 (74.9)              | 43 (86)                | 0.08|
| Antibiotics              | 223 (49.2)              | 41 (80.4)              | <0.0001|
| Bronchodilators          | 215 (46.6)              | 29 (58)                | 0.12|
| Oxygen supplementation   | 173 (37.7)              | 48 (94.1)              | <0.0001|
| Intravenous fluid therapy | 161 (35.2)            | 43 (87.8)              | <0.0001|
| Underlying health conditions |                    |                        |     |
| Any                      | 113 (24.2)              | 29 (56.9)              | <0.001|
| Moderate or severe persistent asthma | 30 (6.4) | 5 (9.8) | 0.36|
| Other chronic lung disorders (e.g. cystic fibrosis, bronchopulmonary dysplasia, obliterant bronchiolitis) | 15 (3.2) | 4 (7.8) | 0.11|
| Immunosuppression (because of underlying disease and/or therapy) or immunodeficiency | 28 (6) | 8 (15.7) | <0.01|
| Neurological or neuromuscular disorders | 22 (4.7) | 8 (15.7) | <0.01|
| Heart disease            | 23 (4.9)                | 4 (7.6)                | 0.33|
| Complications            |                        |                        |     |
| Any                      | 85 (18.2)               | 47 (92.2)              | <0.0001|
| Confirmed or suspected bacterial pneumonia | 52 (11.1) | 20 (39.2) | <0.0001|

Statistically significant differences are shown in bold.
In a multivariable model that included underlying medical conditions, lymphocyte count and chest radiograph result, we identified four statistically significant risk factors associated with PICU admission: underlying neurological or neuromuscular disease \[P = 0.006, \text{Odds Ratio (OR)} 4.2, 95\% \text{ CI 1.5–13.2}\], immunosuppression \[P = 0.008, \text{OR 4.4, 95\% CI 1.5–13.2}\], abnormal initial chest X-ray \[P = 0.005, \text{OR 5.2, 95\% CI 1.7–16.5}\], and lymphocytes under 1840 cells/mm\(^3\) \[P = 0.006, \text{OR 2.9, 1.3–6.2}\]. The estimated effects in this model were similar to those estimated in the previous univariate analysis. The area under the ROC curve was 0.720 (95\% CI 0.66–0.80).

**Mortality**

Five patients (0.9\%) died, all of them suffering of underlying health conditions. Two children (both 4 years old) had leukemia with severe pancytopenia and developed acute respiratory distress with refractory hypoxemia. A 10-year-old patient had a malignant peripheral nerve sheath tumor with cerebral metastasis. He developed bronchopneumonia and acute respiratory distress syndrome with progressive worsening, and limitation of therapeutic effort was decided. A 3-month-old infant with Edwards’ syndrome developed respiratory insufficiency with severe hypoxemia, and limitation of therapeutic effort was decided. The last patient was 4 years old and had a severe encephalopathy with cerebral palsy and a seizure disorder. Her chest radiograph showed a large pleural effusion and developed severe breathing difficulty and refractory hypoxemia. Four out of five of these patients, the exception being the one affected by Edwards’ syndrome, received oseltamivir, were admitted to PICU and put on mechanical ventilation.

**Discussion**

Children hospitalized for pH1N1 infections in Madrid had a wide spectrum of clinical pictures, ranging from mild respiratory symptoms and fever to severe illness and death. The majority of children in our study were less than 5 years of age. Presenting features and median length of hospital stay were similar to those described in other series.\(^5,15,16\) Underlying medical conditions were frequent, mainly asthma, immunosuppression, and neurological disease. Patients with underlying health conditions were older than previously healthy children. Abnormal chest radiograph, low lymphocytes, and underlying health conditions were associated with PICU admission, while asthma was not.

Infants less than 1 year have been considered at increased risk for influenza-related complications only on the basis of age and had the highest hospitalization rates at the beginning of the pandemic.\(^17\) In our study, the clinical course was similar in this age group than in older children, which could be related to a higher hospitalization rate among infants (even when presenting with mild symptoms) and to the fact that the majority of infants were previously healthy. Perhaps, children less than 1 year did not yet have the opportunity to be diagnosed with some of the high-risk medical conditions that increase the risk for severe disease. A recent pediatric study showed that older hospitalized children with pH1N1 were significantly more likely to require PICU admission than hospitalized children <2 years of age.\(^7\) Besides, previous studies of seasonal influenza in Spain did not find more complications among hospitalized infants younger than 6 months.\(^18,19\) Notably, there was only one death in the infant group, and the patient suffered from Edwards’ syndrome. Oseltamivir treatment was significantly less likely in infants less than 1 year of age, although an Emergency Use Authorization was issued temporarily allowing its use in infants during the H1N1 pandemic. However, some pediatricians may have been reluctant to use oseltamivir because of the limited data in patients younger than 1 year of age.

Overall, asthma was the most frequent underlying health condition (31.5\% of cases, including intermittent asthma), as other authors have reported.\(^5,14,20\) It seems that children admitted to hospital with pH1N1 are more likely to have asthma than those with seasonal influenza.\(^7,21\) To our knowledge, there are no published data assessing the severity of pH1N1 infection across different asthma severity levels. In our case series, most hospitalized children with asthma and no other health conditions had intermittent asthma (79\%), suggesting that children with intermittent asthma are at risk of pH1N1 infection requiring hospital admission, which is in accordance with other pediatric series.\(^20,21\) However, when analyzing severity of pH1N1 in patients with asthma in our series (PICU admission, death), it was similar to that of children without underlying medical conditions, and also similar in each asthma severity level. Nevertheless, only one child suffered from severe persistent asthma, and this may limit the validity of our results in this group of patients.

PICU admission rates range from 5.4 to 27\% in the literature.\(^5,7,15,16,21–23\) Our rate of 10\% is similar to that of seasonal influenza.\(^21,24–26\) As it has been previously reported, PICU admission and mechanical ventilation have occurred mainly in children with known comorbidities.\(^27,28\) The proportion of high-risk medical conditions among patients admitted to intensive care units is similar to that reported for adults in our country. However, for adults, the most common underlying medical condition was obesity.\(^29\) In our series, immunosuppression and neurological disorders were the most common underlying medical conditions among PICU patients, and they were significantly associated with PICU admission. Several reports on seasonal influenza had previously shown the importance of neuro-
logical and neuromuscular conditions as a predisposing risk factor for severe disease.\textsuperscript{30–32} As for pH1N1 influenza, it seems that these patients are also at higher risk for complications and PICU admission, mainly those children with multiple developmental diagnoses and/or comorbid pulmonary conditions.\textsuperscript{2,22,23,34} The underlying mechanisms of vulnerability in these children may include problems with muscle tone, weakness, inadequate clearance of respiratory tract secretions, and susceptibility to recurrent respiratory infections.\textsuperscript{32,33} Complicated cases among children are mostly attributable to secondary bacterial infection, which is more common in children than in adults.\textsuperscript{35} The incidence of suspected bacterial pneumonia was similar to the one reported for seasonal influenza.\textsuperscript{31,36} The low rate of confirmed bacterial coinfections in our study is similar to that observed in other pH1N1 case series,\textsuperscript{9,33} in which \textit{S. pneumoniae} has also been the most frequent isolated pathogen.\textsuperscript{5,15} However, bacterial diagnostic tests were not performed in all cases, and many patients received antibiotics around the time of culture collection, which could have reduced the diagnostic sensitivity.\textsuperscript{33} In hospitalized patients with seasonal influenza, culture-proven bacterial infection is also rare, and \textit{S. aureus} and \textit{S. pneumoniae} are the predominant pathogens isolated.\textsuperscript{24} Notably, there were no \textit{S. aureus} infections in our series. In Spain, community-acquired staphylococcal pneumonia is rare, but infections caused by methicillin-resistant \textit{S. aureus} are emerging.\textsuperscript{37} A coinfection by methicillin-resistant \textit{S. aureus} and pandemic influenza H1N1 was recently documented in a child in our country.\textsuperscript{38}

During the 2009 influenza H1N1 pandemic, global hospitalization rates have been higher for children less than the age of 5 years, but the need for mechanical ventilation and the overall case fatality rate among hospitalized patients appears to be lowest among children.\textsuperscript{20,22,29,35,39,40} Mortality proportions among hospitalized children with pH1N1 show marked differences; from 0\textsuperscript{21,28} to 5\%.\textsuperscript{15} Most pediatric deaths have affected patients with underlying medical conditions.\textsuperscript{5,15,27,34} Our mortality data are comparable to seasonal influenza, with the likely exception of the 2003–2004 H3N2 season, which was associated with increased mortality and morbidity.\textsuperscript{30,31,36}

There are several limitations in our study. First, although data recording was standardized, observations may have differed among hospitals or healthcare providers, and not all information was collected for all patients. Second, routine diagnostic testing recommended by public health authorities for hospitalized children with fever and respiratory symptoms may have led to a greater number of confirmed cases than in previous influenza seasons. Third, admission criteria may have not been the same in all the hospitals that participated in the study.

However, we provide global information from a large sample, not only from tertiary care pediatric hospitals but also from local hospitals. Diagnostic methods were the same among all centers and during the whole study period.

In conclusion, pH1N1 in hospitalized children in Madrid (Spain) has affected mainly children less than 5 years of age, and asthma was the most common underlying medical condition. Children less than 1 year were less likely to have high-risk health conditions and develop complications. Patients with predisposing health conditions, especially those with neurological disease, were more likely to experience severe pH1N1 infection. Therefore, this group of children should be carefully assessed for early recognition and adequate follow-up and treatment of pH1N1 infection. As for asthmatic patients, although they did not experience more severe disease, it seems that even children with intermittent asthma are at risk of pH1N1 infection requiring hospital admission and should therefore receive vaccination and be considered for early antiviral therapy.

**Addendum**

This is a multicentric study conducted in 18 different hospitals by a Study Group. In each hospital, there was at least one investigator (depending on the number of cases), who collected data and contributed to their interpretation. All authors have revised the intellectual content of the manuscript.

**Conflicts of interest**

The authors declare to have no conflicts of interest.

**References**

1. Echevarría-Zuno S, Mejía Aranguré JM, Mar-Obeso AI et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374:2072–2079.
2. Editorial Team. Pandemic phase level 4: human cases of the novel influenza A/H1N1 strain confirmed in Scotland and Spain. Euro Surveill 2009; 14:19185.
3. Comunidad de Madrid. Informe semanal de gripe. Temporada 2009–2010 [portal de sanidad de la Comunidad de Madrid]. Available at http://www.madrid.org/sanidad/profesional/informaciontecnica/saludpublica/vigilanciaepid/vigilanciadelagripe/incidenciasemanal-aldegrpe (Accessed 31 March 2010).
4. European Centre for Disease Prevention and Control. The 2009 A(H1N1) Pandemic in Europe. Stockholm: ECDC, 2010.
5. Bettinger JA, Sauvé LJ, Scheifele DW et al. Pandemic influenza in Canadian children: a summary of hospitalized pediatric cases. Vaccine 2010; 28:3180–3184.
6. Hackett S, Hill L, Patel J et al. Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK. Lancet 2009; 374:605.
7. Bagdure R, Curtis DJ, Dobyns E, Glode MP, Dominguez SR. Hospitalized children with 2009 pandemic influenza A (H1N1): compari-
son to seasonal influenza and risk factors for admission to the PICU. PLoS One 2010; 5:e15173.

8 Stein M, Tasher D, Glikman D et al. Hospitalization of children with influenza A (H1N1) virus in Israel during the 2009 outbreak in Israel: a multicenter survey. Arch Pediatr Adolesc Med 2010; 164:1015–1022.

9 Launey E, Ovetchkine P, Saint-Jean M et al. Novel influenza A (H1N1): clinical features of pediatric hospitalizations in two successive waves. Int J Infect Dis 2011; 15:e122–e130.

10 Comunidad de Madrid. Boletín Epidemiológico de la Comunidad de Madrid 2010; 2:3–56. Available at http://www.madrid.org/cs/Satellite?c=PTSA_Generico_FA&cida=1142593584355&language=es&pageid=1142336590538&pageName=PortalSalud%2FPTSA_Generico_FA%2FPTSA_pintarGenericoindice&p=1142336587119&vest=1156329914017 (Accessed 7 January 2011).

11 Comunidad de Madrid. Criterios para la toma de muestras de gripe A (H1N1)[portal de sanidad de la Comunidad de Madrid]. 2009. Available at http://www.madrid.org/cs/Satellite?c=PTSA_Generico_FA&cida=1142548723512&language=es&pageName=PortalSalud%2FPage%2FPTSA_pintarContenidoFinal&vest=1156329914017 (Accessed 10 October 2010).

12 CDC. CDC protocol of real-time RT-PCR for influenza A H1N1. 2009.

13 Marías J, Rogrigo C, Moreno-Pérez D et al. Recomendaciones sobre el tratamiento de la gripe en pediatría (2009–2010). An Pediatr (Barc) 2010; 72:144.e1–144.e12.

14 GEMA 2009. Guía española para el manejo del asma. 2009. Available at http://www.gemasma.com (Accessed 15 February 2011).

15 Libster B, Bugna J, Covillo S et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 2010; 362:45–55.

16 Kumar S, Havens PL, Chusid MJ, Willoughby RE, Simpson P, Henrickson KJ. Clinical and epidemiological characteristics of children hospitalized with 2009 pandemic H1N1 influenza A infection. Pediatr Infect Dis J 2010; 29:591–594.

17 Domínguez-Cherit G, Lapinsey SE, Macias AE et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880–1887.

18 Aróstegui Kareaga N, Montes M, Pérez-Yarza EG, Sardón O, Vicente D, Cilia G. Características clínicas de los niños hospitalizados por infección por virus influenza. An Pediatr (Barc) 2005; 62:5–12.

19 Calvo Rey C, García García ML, Casas Flecha I, Martín del Valle F, Centeno Jiménez M, Pérez-Brehé P. Infecciones por virus de la gripe en menores de dos años. An Pediatr (Barc) 2005; 63:22–28.

20 Nguyen-Van-Tam JS, Openshaw PJM, Hashim A et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May–September 2009). Thorax 2010; 65:645–651.

21 O’Riordan S, Barton M, Yau Y, Read SE, Allen U, Tran D. Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza. CMAJ 2009; 182:39–44.

22 Kumar A, Zarychanski R, Pinto R et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302:1872–1879.

23 Louie JK, Gavali S, Acosta M et al. Children hospitalized with 2009 novel influenza A(H1N1) in California. Arch Pediatr Adolesc Med 2010; 164:1023–1031.

24 Schrag SJ, Shay DK, Gershman K et al. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003–2004. Pediatr Infect Dis J 2006; 25:395–400.

25 Burton C, Vaudry V, Moore DL et al. Children hospitalized with influenza during the 2006–2007 season: a report from the Canadian Immunization Monitoring Program, Active (IMPACT). Can Commun Dis Rep 2008; 34:17–32.

26 Wootton S, Scheifele DW, Mozel M et al. The epidemiology of influenza in children hospitalized in Canada, 2004–2005, in Immunization Monitoring Program Active (IMPACT) centres. Can Commun Dis Rep 2006; 32:65–74.

27 Lister P, Reynolds F, Parslow R et al. Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children. Lancet 2009; 374:605–607.

28 Lockman JL, Fischer WA, Perl T, Valsamakis A, Nichols DG. The critically ill child with novel H1N1 influenza A: a case series. Pediatr Crit Care Med 2010; 11:173–178.

29 Rello J, Rodríguez A, Ibáñez P et al. Intensive care adult patients with severe respiratory failure caused by influenza A(H1N1) in Spain. Crit Care 2009; 13:R148.

30 Bhat N, Wright JG, Broder KR et al. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med 2005; 353:2559–2567.

31 Coffin SE, Zaoutis TE, Wheeler AB et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics 2007; 119:740–748.

32 Keren R, Zaoutis TE, Bridges CB et al. Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza. JAMA 2005; 294:2188–2194.

33 Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 2009; 361:1935–1944.

34 CDC. Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection – United States, April–August 2009. MMWR Morb Mortal Wkly Rep 2009; 58:941–947.

35 Rothenberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med 2010; 38:e91–e97.

36 Ampofo K, Gesteland PH, Bender J et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics 2006; 118:2409–2417.

37 Brosena A, Chaves F, Rojo P, Otero JR. Emergencia de un clon de Staphylococcus aureus resistente a meticolina de origen comunitario en la población pediátrica del sur de Madrid. Enferm Infecc Microbiol Clin 2006; 24:31–35.

38 Obando I, Valderrabanos ES, Millán JA, Neth OW. Necrotising pneumonia due to influenza A (H1N1) and community-acquired methicillin-resistant Staphylococcus aureus clone USA300: successful management of the first documented paediatric case. Arch Dis Child 2010; 95:305–306.

39 Vaillant L, La Ruche G, Tarantola A, Barboza P; for the epidemic intelligence team at InVS. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 2009; 14:19309.

40 Pérez-Padilla R, de la Rosa-Zamboni D, Ponce de León S et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680–689.